HYPOGAMMAGLOBULINEMIA
Clinical trials for HYPOGAMMAGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new HYPOGAMMAGLOBULINEMIA trials appear
Sign up with your email to follow new studies for HYPOGAMMAGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for blood cancer patients: drug aims to slash infection risk
Disease control Recruiting nowThis study tests whether a medicine called XEMBIFY, given every two weeks alongside standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody lev…
Matched conditions: HYPOGAMMAGLOBULINEMIA
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can a simple antibody infusion shield myeloma patients from infections?
Disease control Recruiting nowThis study tests whether IgPro20 (HIZENTRA), a concentrated antibody solution given under the skin, can prevent infections in people with multiple myeloma who have low antibody levels due to bispecific antibody therapy. About 100 participants will either receive IgPro20 plus stan…
Matched conditions: HYPOGAMMAGLOBULINEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Fatigue in MS might be caused by low antibodies – new study investigates
Knowledge-focused Recruiting nowThis study looks at whether low levels of immunoglobulin G (IgG), a type of antibody, are linked to fatigue in people with multiple sclerosis (MS). Researchers will compare fatigue scores and infection rates between MS patients with low IgG and those with normal IgG. The goal is …
Matched conditions: HYPOGAMMAGLOBULINEMIA
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC